RT Journal Article
SR Electronic
T1 Lipid-Modulating Agents for Prevention or Treatment of COVID-19 in Randomized Trials
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.05.03.21256468
DO 10.1101/2021.05.03.21256468
A1 Azita H. Talasaz
A1 Parham Sadeghipour
A1 Maryam Aghakouchakzadeh
A1 Isaac Dreyfus
A1 Hessam Kakavand
A1 Hamid Ariannejad
A1 Aakriti Gupta
A1 Mahesh V. Madhavan
A1 Benjamin W. Van Tassell
A1 David Jimenez
A1 Manuel Monreal
A1 Muthiah Vaduganathan
A1 John Fanikos
A1 Dave L Dixon
A1 Gregory Piazza
A1 Sahil A. Parikh
A1 Deepak L. Bhatt
A1 Gregory YH Lip
A1 Gregg W. Stone
A1 Harlan M. Krumholz
A1 Peter Libby
A1 Samuel Z. Goldhaber
A1 Behnood Bikdeli
YR 2021
UL http://medrxiv.org/content/early/2021/05/05/2021.05.03.21256468.abstract
AB Coronavirus disease 2019 (COVID-19) is associated with systemic inflammation, endothelial activation, and multi-organ manifestations. Lipid modulating agents may be useful in treating patients with COVID-19. They may inhibit viral entry by lipid raft disruption or ameliorate the inflammatory response and endothelial activation. In addition, dyslipidemia with lower high-density lipoprotein cholesterol and higher triglycerides portends worse outcome in patients with COVID-19. Upon a systematic search, 40 RCTs with lipid modulating agents were identified, including 17 statin trials, 14 omega-3 fatty acids RCTs, 3 fibrates RCTs, 5 niacin RCTs, and 1 dalcetrapib RCT for management or prevention of COVID-19. This manuscript summarizes the ongoing or completed randomized controlled trials (RCTs) of lipid modulating agents in COVID-19 and the implications of these trials for patient management.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNoneAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Not applicable.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData availability only after permission of corresponding authorACE2angiotensin converting enzyme 2ARDSacute respiratory distress syndromeCETPcholesterol ester transfer proteinCOVID-19coronavirus disease 2019HDLhigh-density lipoproteinHMG-CoA3-hydroxy-3-methyl-glutaryl-coenzyme AICUintensive care unitNADnicotinamide adenine dinucleotideRCTrandomized controlled trialSARS-CoV-2severe acute respiratory syndrome coronavirus 2